TY - JOUR
T1 - Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab
AU - Zhao, Haifeng
AU - Zhang, Le
AU - Guo, Shanqi
AU - Yuan, Tian
AU - Xia, Bing
AU - Qu, Fu Lian
AU - Zhang, Lianyu
AU - Zhang, Yizhuo
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/10
Y1 - 2014/10
N2 - The aim of this study was to detect the expression levels of Dicer1, Drosha, DGCR8, and Ago2 messenger ribonucleic acids (mRNAs) in patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) and determine their associations with clinical parameters and prognostic significance. The mRNA level expressions of Dicer1, Drosha, DGCR8, and Ago2 were detected by real-time quantitative polymerase chain reaction. Immunohistochemical staining of CD10, BCL6, and MUM1 was performed using EnVision™ system. The clinicopathologic features and follow-up data were analyzed using Kaplan–Meier estimator. The results show that the expression of Dicer1 (P = 0.001), Drosha (P = 0.01), DGCR8 (P = 0.02), and Ago2 (P = 0.002) mRNAs in cancer tissues of patients with PGI-DLBCL was significantly lower than those in normal tissues of healthy controls. Among the expression of CD10, BCL6, and MUM1, 27.4 % (17/62) of the patients belonged to the germinal center B-cell (GCB) subtype and 72.6 % (45/62) belonged to the non-GCB subtype. Dicer1 expression was significantly decreased in the non-GCB subgroup (P = 0.02) and in the high International Prognostic Index (3–5 score) subgroup (P = 0.03). Kaplan–Meier analysis showed that the low-Dicer1 subgroup had a shorter overall survival (P = 0.02) and shorter progression-free survival (P = 0.015) than the high-Dicer1 subgroup. Multivariate analysis identified Dicer1 as an independent prognostic factor in PGI-DLBCL. In Conclusion, Dicer1, Drosha, DGCR8, and Ago2 play key roles in the pathogenesis of PGI-DLBCL. Dicer1, an independent prognostic factor for predicting shortened survival of patients with PGI-DLBCL, can be used as a biomarker to guide the prognosis.
AB - The aim of this study was to detect the expression levels of Dicer1, Drosha, DGCR8, and Ago2 messenger ribonucleic acids (mRNAs) in patients with primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) and determine their associations with clinical parameters and prognostic significance. The mRNA level expressions of Dicer1, Drosha, DGCR8, and Ago2 were detected by real-time quantitative polymerase chain reaction. Immunohistochemical staining of CD10, BCL6, and MUM1 was performed using EnVision™ system. The clinicopathologic features and follow-up data were analyzed using Kaplan–Meier estimator. The results show that the expression of Dicer1 (P = 0.001), Drosha (P = 0.01), DGCR8 (P = 0.02), and Ago2 (P = 0.002) mRNAs in cancer tissues of patients with PGI-DLBCL was significantly lower than those in normal tissues of healthy controls. Among the expression of CD10, BCL6, and MUM1, 27.4 % (17/62) of the patients belonged to the germinal center B-cell (GCB) subtype and 72.6 % (45/62) belonged to the non-GCB subtype. Dicer1 expression was significantly decreased in the non-GCB subgroup (P = 0.02) and in the high International Prognostic Index (3–5 score) subgroup (P = 0.03). Kaplan–Meier analysis showed that the low-Dicer1 subgroup had a shorter overall survival (P = 0.02) and shorter progression-free survival (P = 0.015) than the high-Dicer1 subgroup. Multivariate analysis identified Dicer1 as an independent prognostic factor in PGI-DLBCL. In Conclusion, Dicer1, Drosha, DGCR8, and Ago2 play key roles in the pathogenesis of PGI-DLBCL. Dicer1, an independent prognostic factor for predicting shortened survival of patients with PGI-DLBCL, can be used as a biomarker to guide the prognosis.
KW - Dicer1
KW - Diffuse large B-cell lymphoma
KW - Gastrointestinal lymphoma
KW - Immunophenotype
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84919902803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919902803&partnerID=8YFLogxK
U2 - 10.1007/s12032-014-0206-2
DO - 10.1007/s12032-014-0206-2
M3 - Article
C2 - 25195038
AN - SCOPUS:84919902803
SN - 1357-0560
VL - 31
SP - 1
EP - 7
JO - Medical Oncology
JF - Medical Oncology
IS - 10
M1 - 206
ER -